Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287445 | 1.00 | BACE1 (0.41) | BACE1HCRTR1HCRTR2CNR2BACE2 | |
| SCHEMBL297851 | 0.93 | BACE1 (0.40) | BACE1HCRTR1HCRTR2CNR2BACE2 | |
| SCHEMBL297852 | 0.93 | BACE1 (0.40) | BACE1HCRTR1HCRTR2CNR2BACE2 | |
| SCHEMBL296639 | 0.85 | MAPT (0.42) | BACE1HCRTR1HCRTR2 | |
| SCHEMBL296638 | 0.85 | MAPT (0.42) | BACE1HCRTR1HCRTR2 | |
| SCHEMBL299155 | 0.85 | BACE1 (0.47) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL299154 | 0.85 | BACE1 (0.47) | BACE1HCRTR1HCRTR2BACE2 | |
| SCHEMBL568651 | 0.79 | MAPT (0.41) | BACE1 | |
| SCHEMBL568652 | 0.79 | MAPT (0.41) | BACE1 | |
| SCHEMBL287405 | 0.78 | BACE1 (0.40) | BACE1HCRTR1HCRTR2BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461160-B2 | Dihydropyrimidinones | HOFFMANN-LA ROCHE, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2427437-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | BACE1 2/4885HCRTR1 807/4885HCRTR2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.